AbCellera Biologics Inc. (ABCL) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities.
Is AbCellera Biologics Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, AbCellera Biologics Inc. (ABCL) trades at $12.27 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: AbCellera Biologics Inc.
Market cap $4B · 52 weeks $3 – $15 (17 % below the high) · P/E no earnings · Dividend none · Next earnings November 9, 2026 · expected EPS -$0.17 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/Sales 12.4× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 5.1 %, fails.
- Market cap / Cash 6.9×, fails.
- Cash Runway 49 months, passes.
- Total Debt 0.3×, passes.
- Annual cash burn $0.44, info.
Against its peers (reference peers) — AbCellera Biologics Inc.: P/E —; EV/EBITDA —; ROIC -14.9 %; $4.0B. Arcutis Biotherapeutics, Inc. (P/E 154×; EV/EBITDA 94.7×; ROIC 9.9 %; $4.0B), Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.4×; ROIC 5.7 %; $5.0B).
Profitability
| Return on Equity | -17.49% |
| Return on Invested Capital | -14.95% |
| Return on Assets | -12.59% |
| Gross Margin | 74.95% |
| Operating Margin | -340.25% |
| Net Margin | -248.83% |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 12.77 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.66 |
Price Performance
| 1 month | -10.70% |
| 3 months | +101.48% |
| Year-to-date | +258.77% |
| 1 year | +121.08% |
| 3 years | +161.06% |
| 5 years | -30.36% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ABCL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks